Feb. 23 at 5:15 PM
$BBNX Robert W. Baird cut its target price to
$14 (from
$28) and kept a "neutral" rating, a move that implies essentially no near-term upside from current levels.
Beta Bionics beat Q4 consensus (EPS of (
$0.30) vs. (
$0.42)) and reported revenue of
$32.1M, raised its 2026 revenue guidance to about
$130–
$135M, and cited strong commercial traction with an installed base up ~129% YoY.
Profitability and legal/insider overhangs persist — negative margins and adjusted EBITDA remain a concern, insiders recently sold shares and two law firms have opened investor investigations, even as the analyst consensus sits at a "Moderate Buy" with a
$25 average price target.
🥳🥳🥳
